Cannabis feels so meta sometimes.
TLRY leads a 10x market run and then collapses to the worst performing Cannabis company in 2021 lol.
Man APHA definitely getting the short end of the stick here haha but they'll all make plenty of money slangin drugs together.
Wish I had done a mashup like this a long time ago, lots of fun data.
Here's how I've been betting it:
1. APHA/TLRY (TLRY was my #3 before the merger)
2. CGC
3. ACB
4. OGI
I threw in GRWG and CLVR here too.
GRWG is the shovels and pickaxes of this Green Gold Rush.
CLVR a new entrant that looks promising.
I have some other minor stakes but these are the Gems.
TLRY/APHA leading the pack with OGI coming out of left field recently to supplant ACB and CGC.
With OGI finally blowing up, that makes CGC the best value play right now. At similar value, CGC much better company than ACB.
Lookin to pick up another load around $23-$26 and we're back on the hunt for that double top ;).
APHA and TLRY are priced pretty well here, OGI lookin pretty overpriced. Rest are underpriced.
TLRY leads a 10x market run and then collapses to the worst performing Cannabis company in 2021 lol.
Man APHA definitely getting the short end of the stick here haha but they'll all make plenty of money slangin drugs together.
Wish I had done a mashup like this a long time ago, lots of fun data.
Here's how I've been betting it:
1. APHA/TLRY (TLRY was my #3 before the merger)
2. CGC
3. ACB
4. OGI
I threw in GRWG and CLVR here too.
GRWG is the shovels and pickaxes of this Green Gold Rush.
CLVR a new entrant that looks promising.
I have some other minor stakes but these are the Gems.
TLRY/APHA leading the pack with OGI coming out of left field recently to supplant ACB and CGC.
With OGI finally blowing up, that makes CGC the best value play right now. At similar value, CGC much better company than ACB.
Lookin to pick up another load around $23-$26 and we're back on the hunt for that double top ;).
APHA and TLRY are priced pretty well here, OGI lookin pretty overpriced. Rest are underpriced.
Data analyst with a passion for best fit lines B)
相關出版品
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
Data analyst with a passion for best fit lines B)
相關出版品
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。